title: Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
authors.forename: Allan
authors.initials: A
authors.lastname: Rodriguez
authors.forename: Christina
authors.initials: C
authors.lastname: Hill-Zabala
authors.forename: Louis
authors.initials: L
authors.lastname: Sloan
authors.forename: Thomas
authors.initials: T
authors.lastname: Jefferson
authors.forename: Linda
authors.initials: L
authors.lastname: Yau
authors.forename: Maria
authors.initials: M
authors.lastname: Watson
authors.forename: David
authors.initials: D
authors.lastname: Irlbeck
authors.forename: Mark
authors.initials: M
authors.lastname: Shaefer
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D018579:Patient Selection; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D018119:Stavudine